Palme Carsten E, O'Brien Christopher J, Veness Michael J, McNeil Edward B, Bron Luc P, Morgan Gary J
Sydney Head & Neck Cancer Institute, Royal Prince Alfred Hospital, Australia.
Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):750-3. doi: 10.1001/archotol.129.7.750.
To test a new clinical staging system in patients with metastatic cutaneous squamous cell carcinoma involving the parotid gland or lymph nodes of the neck.
Retrospective analysis of clinicopathological data from patients with a minimum of 2 years' follow-up.
Multidisciplinary head and neck unit in a tertiary referral center.
Between 1987 and 1999, 126 patients (104 men and 22 women; median age, 69 years) were treated for metastatic cutaneous squamous cell carcinoma involving the parotid and/or neck.
Locoregional recurrence and disease-specific survival.
Of the 126 patients, disease involved the parotid gland in 81 patients, of whom 14 also had clinical neck disease, while 45 patients had neck involvement only. Parotid stages were as follows: P0, 45 patients; P1, 55; P2, 20; and P3, 6. Neck stages were: N0, 67 patients; N1, 31; and N2, 28. Treatment involved combined surgery and radiotherapy in 93 patients, surgery alone in 12, and radiotherapy alone in 18. Three patients received palliative treatment only. There were 47 therapeutic and 40 elective neck dissections. Pathologic evaluation demonstrated parotid involvement in 70 patients and neck involvement in 51, representing 44 therapeutic and 7 elective neck dissections. Disease involved both the parotid and neck in 19 patients. The 5-year local (parotid) control rate was 80% and this varied statistically significantly with P stage. Parotid stages 2 and 3 were independent risk factors for a decrease in local control rate using multivariate analysis. The 5-year disease-specific survival rate for the entire group was 68% and P stage significantly influenced survival: P0, 60%; P1, 81%; P2, 51%; and P3, 33% (P<.001). Pathological involvement of neck nodes did not worsen survival of patients with parotid disease. Overall multivariate analysis demonstrated that single-modality therapy, P3 stage, and presence of immunosuppression independently predicted a decrease in survival.
These results confirm that the extent of metastatic disease in the parotid gland significantly influences outcome and suggests that staging the parotid separately in metastatic cutaneous squamous cell carcinoma may be useful. Further evaluation of the recommended staging changes with a larger patient cohort will be required to clarify the influence of neck node involvement.
在转移性皮肤鳞状细胞癌累及腮腺或颈部淋巴结的患者中测试一种新的临床分期系统。
对随访至少2年的患者的临床病理数据进行回顾性分析。
一家三级转诊中心的多学科头颈科。
1987年至1999年期间,126例患者(104例男性和22例女性;中位年龄69岁)接受了转移性皮肤鳞状细胞癌累及腮腺和/或颈部的治疗。
局部区域复发和疾病特异性生存率。
126例患者中,81例疾病累及腮腺,其中14例同时有颈部临床病变,45例仅累及颈部。腮腺分期如下:P0,45例患者;P1,55例;P2,20例;P3,6例。颈部分期为:N0,67例患者;N1,31例;N2,28例。93例患者接受了手术和放疗联合治疗,12例仅接受手术,18例仅接受放疗。3例患者仅接受了姑息治疗。进行了47例治疗性和40例选择性颈部淋巴结清扫术。病理评估显示70例患者有腮腺受累,51例有颈部受累,分别代表44例治疗性和7例选择性颈部淋巴结清扫术。19例患者疾病同时累及腮腺和颈部。5年局部(腮腺)控制率为80%,且随P分期有显著统计学差异。腮腺2期和3期是多因素分析中局部控制率降低的独立危险因素。整个组的5年疾病特异性生存率为68%,P分期显著影响生存率:P0,60%;P1,81%;P2,51%;P3,33%(P<0.001)。颈部淋巴结的病理累及并未使腮腺疾病患者的生存率降低。总体多因素分析表明,单模式治疗、P3期和免疫抑制的存在独立预测生存率降低。
这些结果证实腮腺转移性疾病的范围显著影响预后,并表明在转移性皮肤鳞状细胞癌中对腮腺进行单独分期可能有用。需要用更大的患者队列进一步评估推荐的分期变化,以阐明颈部淋巴结受累的影响。